Concepedia

Ludmyla Rekeda

LR

Statistics

Publications

15

Citations

1.3K

H-Index

15

Active since

2005

Affiliations

Allergan (United States)(Current)

Almirall (Spain)

Novartis (Switzerland)

Novartis (United States)

Stanford University

Ludmyla Rekeda is an author at Allergan (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top concepts

Publications per year

2005–2023

15

Publications

15

Differential Effects of the Antimuscarinic Agents Darifenacin and Oxybutynin ER on Memory in Older Subjects

Gary G. Kay, Thomas H. Crook, Ludmyla Rekeda et al. · European Urology · 2006 · 298 citations

, , +12

Efficacy and safety of cariprazine in bipolar I depression: A double‐blind, placebo‐controlled phase 3 study

Willie Earley, Maria Victoria Burgess, Barbara Khan et al. · Bipolar Disorders · 2019 · 243 citations · Full text

Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study

Willie Earley, Maria Victoria Burgess, Ludmyla Rekeda et al. · American Journal of Psychiatry · 2019 · 153 citations · Full text

Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β <sub>2</sub> -Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE <sup>2</sup> SPOND). A Randomized Clinical Trial

Fernando J. Martínez, Klaus F. Rabe, Sanjay Sethi et al. · American Journal of Respiratory and Critical Care Medicine · 2016 · 121 citations

Darifenacin treatment of patients ≥ 65 years with overactive bladder: results of a randomized, controlled, 12-week trial

Christopher R. Chapple, Catherine E. DuBeau, Ursula Ebinger et al. · Current Medical Research and Opinion · 2007 · 91 citations

1–5 of 15